Prionpeptide185-208

ProductCode:SP-P-02

Majorprionproteinpeptide185-208(Swiss-ProtID:P04156)ofHomosapiens(Human).
Aminoacidsequence:KQHTVTTTTKGENFTETDVKMMER
Amount:1vial(1mg)
Purity:>90%(HPLC-MS)
DeliveryFormat:Freezedriedinambertypeglassvial
Application(s):Invitrostaining,Westernblot,Bindingexperiments
Indication(s)/Topic(s):Infection,Neurodegenerativedisease,TransmissIBLespongiform
DeliveryTime:2-5days

JPT"sSingleCatalogPeptides
JPTPeptideTechnologieshassubstantial,long-standingexpertiseinprovidingcustompeptides,peptidomimetics,andproteinstotheglobalscientificcommunity.Ourhighlyskilledandcommittedscientificstaffensuresthatthemostappropriatemethodsandtechniquesareselectedforeverysynthesisproject.AllofJPT"scataloguepeptidesareprovidedwithHPLC-MSanalysestoconfirmtheidentityanddemonstratethehighqualityofourpeptides.

BenefitsofJPT"sSingleCataloguePeptides
-WholeproductionperformedinaregulatedEuropeanenvironmentaccordingtoDINENISO9001:2015&GCLPstandards;auditswelcome!
-Synthesisprotocolsdesignedtoavoidtoxiccontaminantsandsideproducts
-ProvisionoffreezedriedaliquotsforenhancedstABIlity
-Proventrackrecordforapplicationsinclinicalstudies

Prionpeptide185-208

SelectedReferences
"CompetitiveMirrorImagePhageDisplayDerivedPeptideModulatesAmyloidBetaAggregationandToxicity"
Rudolphetal.,PLoSOne. (2016)-PMID:26840229
"InhibitionoftheCardiacNa+Channelα-subunitNav1.5byPropofolandDexmedetomidine"
Stoetzeretal.,NaunynSchmiedebergsArchPharmacol.-PMID:26667357
"Aβ-42loweringAgentsFromtheMarine-DerivedFungusDichotomomycesCejpii"
Harmsetal.,Steroids.(2015)-PMID:26440473
"η-SecretaseProcessingofAPPInhibitsNeuronalActivityintheHippocampus"
Willemetal.,Nature(2015)-PMID:26322584
"HybridizationofanAβ-specificAntibodyFragmentwithAminopyrazole-basedβSheetLigandsDisplaysStrikingEnhancementofTargetAffinity"
Hellmertetal.,Org.Biomol.Chem.(2015)-PMID:25613910

ApplicationNote
"SyntheticAmyloidBetaPeptidesAidAlzheimerInvestigation"
Broersenetal.,ApplicationNote(2013)(fulltext)

Testimonial
"OurgroupfocusesontheinvitrostudyofriskfactorsinAlzheimer’sdiseaseand,asweexperiencedthatthein-houseexpressionandproductionoftheamyloidbetapeptideisnotoriouslydifficult,wearecontinuouslydependentonahighqualitysupplyofalargevarietyofthesepeptidesfromcommercialsource.WestartedourcollaborationwithJPTwiththeirrequesttotestarangeoftheirpeptidesfortheabilitytoproducetoxicoligomersandfibrillarnetworksandwereimpressedbytherapidsupplyofaverywiderangeofhighpuritypeptideswithexcellentfibrilformingpropertiesandtoxicityprofiles.JPThasshownrealvaluableknow-howandexperienceinthefieldofpeptidesynthesisbytheirabilitytogeneratehighqualitypreparationsofamyloidbetapeptidevariantswhichareknownfortheirdifficultytohandle."
KerensaBroersen,AssistantProf.,NanobiophysicsGroup,UniversityofTwente,Enschede,TheNetherlands